Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Abia berezowskii

ABSTRACT: Abia berezowskii Genome sequencing

PROVIDER: PRJNA598410 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10828664_1.fastq.gz	Fastqsanger.gz
	SRR10828664_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Abia mutica

Project description:Abia mutica Proteome

| PRJNA843910 | ENA

Abia candens

Project description:Abia candens overview

| PRJNA1143641 | ENA

Abia berezowskii

Project description:Abia berezowskii overview

| PRJNA901591 | ENA

Structure-functional characterization of Lactococcus AbiA phage defense system

Project description:Structure-functional characterization of Lactococcus AbiA phage defense system

| PRJEB71919 | ENA

Abia americana

Project description:Prestige Park Grove Genome sequencing and assembly

| PRJNA898856 | ENA

iyAbiCand

Project description:Abia candens

| PRJEB66085 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

iyAbiCand1

Project description:Abia candens genome assembly, iyAbiCand1

| PRJEB78602 | ENA

Case based rubella surveillance in Abia State, South East Nigeria, 2007-2011.

Project description:Introduction. Rubella infection has the potential of causing severe fetal birth defects collectively called congenital rubella syndrome (CRS) if the mother is infected early in pregnancy. However, little is known about rubella and CRS epidemiology in Nigeria and rubella vaccines are still not part of routine childhood immunization in Nigeria. Methods. Analysis of confirmed cases of rubella in Abia State, Nigeria from 2007 to 2011 detected through Abia State Integrated Disease Surveillance and Response system. Results. Of the 757 febrile rash cases, 81(10.7%) tested positive for rubella immunoglobulin M (IgM). New rubella infection decreased from 6.81/1,000,000 population in 2007 to 2.28/1,000,000 in 2009 and increased to 6.34/1,000,000 in 2011. The relative risk of rubella was 1.5 (CI [0.98-2.28]) times as high in females compared to males and 1.6 times (CI [0.90-2.91]) as high in rural areas compared to urban areas. Eighty six percent of rubella infections occurred in children less than 15 years with a high proportion of cases occurring between 5 and 14 years. Conclusion. Rubella infection in Abia State, Nigeria is predominantly in those who are younger than 15 years old. It is also more prevalent in females and in those living in rural areas of the state. Unfortunately, there is no surveillance of CRS in Nigeria and so the public health impact of rubella infection in the state is not known. Efforts should be made to expand the rubella surveillance in Nigeria to incorporate surveillance for CRS.

| S-EPMC4183961 | biostudies-literature

iyAbiCand

Project description:Abia candens, genomic and transcriptomic data

| PRJEB66084 | ENA